IMU Biosciences

London-headquartered biotechnology firm IMU Biosciences has successfully closed its oversubscribed Series A financing round, securing £40 million ($53 million) in total capital.

Summary of transaction details:

• Value: £40 million ($53 million)
• Sector: Healthcare & Biotech / DeepTech & AI / Precision Medicine
• Advisor: Not disclosed
• Key Entities: Target: IMU Biosciences (Melio Healthcare Ltd); Co-Lead Investors: IQ Capital and Molten Ventures; Participating Investors: British Business Bank, Meltwind, and existing backers; Key Executive: Dr. John Baker (CEO).
• Location: London, UK

Note: Built on decades of pioneering research originating from the Francis Crick Institute and King's College London, IMU Biosciences operates at the intersection of AI, computational biology, and advanced medicine. Traditional diagnostic tools map the immune system through low-resolution, fragmented metrics. IMU’s high-throughput multi-omic platform utilizes proprietary machine learning to process over 100 million immune data points from a simple 2ml blood sample, enabling the real-time classification of 2,500 discrete cell subsets. Having expanded its proprietary dataset to encompass over 25,000 individuals, the capital infusion will be utilized for operational expansion, clinical infrastructure development, and advancing its core predictive screening programs. These include tracking graft efficacy and predicting rejection in stem cell (HSCT) and solid organ transplantation, alongside scaling its involvement in MANIFEST—a major UK research consortium optimizing patient response to cancer immunotherapies.